Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Theratechnologies Confirms Issuance Of U.S. Patent Covering

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Oct 13, 2020 7:52pm

123 Views

Post# 31711685

RE:RE:RE:RE:RE:RE:Theratechnologies Confirms Issuance Of U.S. Patent Covering

Small pop after hours on little volume.

qwerty22 wrote:

I meant to write both work against skinny labels.

qwerty22 wrote:

It's classed as a biologic. The original indication is so different to the NASH indication. Both seem to work against biologics.

Its interesting they only mention tesamorelin, when we first heard about this it was to all GHRH analogs. Is that still true?

Great 1st PR, can we expect more?

Spartrap wrote: Great news indeed.. Unfortunately the patent alone won't protect TH from "skinny labeling" practices by generic drug makers, which will likely end up eating a significant part of the market opportunity, but it's giving a lot more credence to the whole NAFLD/NASH project. Hopefully, the F8 formula will be so much easier that patients will ask for "dispense as written" mentions on the script.

palinc2000 wrote: This is great news,,,,,,We may have a good week